EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial

Matthew Matasar, Nancy L Bartlett, Mazyar Shadman, Lihua E Budde, Ian Flinn, Gareth P Gregory, Won Seog Kim, Georg Hess, Dima El-Sharkawi, Catherine S Diefenbach, Huang Huang, Iris To und 4 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024-04 · 24 (4) · 240-253

DOI: 10.1016/j.clml.2023.12.005 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-04. Verfasst von Matthew Matasar und 15 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, New Brunswick, NJ. Hauptthemen laut MEDLINE: Antineoplastic Agents, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Lymphoma, Follicular. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genentech, Roche Canada, F. Hoffmann-La Roche Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLymphoma, B-CellLymphoma, Non-HodgkinLymphoma, FollicularHumansEurope

Stichwörter der Autor:innen

Adverse eventsBispecific antibodyCytokine release syndromeFollicular lymphomaLymphoid malignancies

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, New Brunswick, NJ.
  • Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO.
  • Fred Hutchinson Cancer Research Center, Seattle, WA.
  • City of Hope National Medical Center, Duarte, CA.
  • Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.
  • Monash Health and School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia.

Förderung

  • Genentech
  • Roche Canada
  • F. Hoffmann-La Roche Ltd

Zitieren

APA

Matasar, M., Bartlett, N. L., Shadman, M., Budde, L. E., Flinn, I., Gregory, G. P., Kim, W. S., Hess, G., El-Sharkawi, D., Diefenbach, C. S., Huang, H., To, I., Parreira, J., Wu, M., Kwan, A., & Assouline, S. (2024). Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Clinical Lymphoma Myeloma and Leukemia, 24(4), 240-253. https://doi.org/10.1016/j.clml.2023.12.005

Vancouver

Matasar M, Bartlett NL, Shadman M, Budde LE, Flinn I, Gregory GP, et al. Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Clinical Lymphoma Myeloma and Leukemia. 2024;24(4):240-253. doi:10.1016/j.clml.2023.12.005

BibTeX
@article{Matasar2024,
  author = {Matasar, Matthew and Bartlett, Nancy L and Shadman, Mazyar and Budde, Lihua E and Flinn, Ian and Gregory, Gareth P and Kim, Won Seog and Hess, Georg and El-Sharkawi, Dima and Diefenbach, Catherine S and Huang, Huang and To, Iris and Parreira, Joana and Wu, Mei and Kwan, Antonia and Assouline, Sarit},
  title = {Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  volume = {24},
  number = {4},
  pages = {240--253},
  doi = {10.1016/j.clml.2023.12.005}
}
Kostenlos starten →